Celiprolol - Acer Therapeutics

Drug Profile

Celiprolol - Acer Therapeutics

Alternative Names: ACER-002; EDSIVO; VASEBRA™

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acer Therapeutics
  • Class Antihypertensives; Heart failure therapies; Ischaemic heart disorder therapies; Phenylurea compounds; Propanolamines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ehlers-Danlos syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ehlers-Danlos syndrome

Most Recent Events

  • 07 Mar 2018 Acer Therapeutics plans to schedule a pre-NDA meeting with the US FDA in the second quarter of 2018
  • 07 Mar 2018 Acer Therapeutics announces intention to submit NDA to the US FDA for Ehlers-Danlos syndrome in the end of the first half of 2018
  • 16 Oct 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top